Delto

Quick links to important sections

Delto

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Delto

This section defines the pharmaceutical product Delto, explaining its core identity, composition, classification, and general therapeutic purpose as a medication.

Property Description
Active ingredient Alprazolam
Form Tablet, Extended-Release Tablet, Orally Disintegrating Tablet, Oral Solution
Pharmacological class Benzodiazepine / Central Nervous System (CNS) Depressant
General purpose Anxiolytic action for nervous system excitability
Origin Synthetic (Triazolobenzodiazepine)

Delto: The Pharmaceutical Identity and Classification

Delto is a synthetic pharmaceutical preparation whose single active ingredient is Alprazolam, a potent compound classified as a triazolobenzodiazepine. This chemical structure places Delto within the high-level pharmacological class of benzodiazepines and functionally defines it as a potent Central Nervous System (CNS) depressant and anxiolytic. The product is a prescription-only medicine, typically associated with manufacturers like Aden Healthcare in India.

Pharmacological data indicates that Alprazolam is readily absorbed after oral administration, achieving peak concentrations in the plasma rapidly. This characteristic indicates the medication is designed to provide quick intervention for symptoms associated with nervous system overactivity. The drug’s general purpose is to modulate this excitability, providing a profound calming, or sedative effect, which is characteristic of the benzodiazepine class.

Composition, Form, and General Anxiolytic Purpose

Delto is a single-ingredient product designed exclusively for the oral route of administration. It is differentiated by being available in several oral dosage forms, including the standard compressed tablet, the orally disintegrating tablet, the extended-release tablet, and a concentrated oral solution.

Its action involves enhancing the function of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), by binding to the GABA-A receptor complex. Clinically, Alprazolam is recognized for achieving symptom relief for generalized anxiety and panic, with a fast onset of action. This means the drug works by strengthening the brain's natural calming processes, ultimately achieving central nervous system tranquility, which is its overarching functional goal.

What side effects are possible with Delto?

Possible Side Effects and Safety Information

The official safety profile of Delto (Alprazolam) is primarily defined by its effects as a Central Nervous System (CNS) depressant. The majority of reported adverse reactions are classified by frequency, based on data from clinical trials and post-marketing reports.

Frequency-Classified Adverse Reactions

The most commonly reported effects, classified as Very Common (ge 10% incidence in trials), include drowsiness, sedation, fatigue, impaired coordination, and constipation. Common adverse reactions (1% to <10% incidence) include dysarthria (slurred speech), confusional state, anxiety, depression, dry mouth, nausea, and changes in appetite or weight. Post-marketing surveillance has documented reactions with an Incidence Not Known, such as angioedema, hepatitis, jaundice, and hypomania/mania.

Serious Safety Considerations

The regulatory labeling includes mandatory warnings regarding the risk of physical dependence and addiction associated with continued use. Abrupt cessation or rapid dose reduction can trigger acute, potentially life-threatening withdrawal reactions, including seizures. A major safety restriction is the severe danger of respiratory depression, coma, and death when Delto is used concomitantly with other CNS depressants, particularly opioids.

Specific Safety Populations and Restrictions

Safety notes for specific groups are explicitly documented. Older adults may exhibit increased sensitivity to the CNS effects, which can increase the risk of severe drowsiness and falls. The drug is contraindicated in individuals with narrow-angle glaucoma and in those receiving strong CYP3A inhibitors due to increased drug exposure. The safety and efficacy of the medication have not been established in the pediatric population.

Overdose and Emergency Response

Delto Overdose and When to Seek Help

Official regulatory information describes a Delto (Alprazolam) overdose as an exaggeration of its core activity as a CNS depressant. Severity is classified as ranging from mild symptoms to life-threatening outcomes.

Element Official Regulatory Description
Documented Overdose Presentations Drowsiness, somnolence, confusion, impaired coordination (ataxia), and diminished reflexes.
Physiological Systems Affected Primary effects on the Central Nervous System (CNS), potentially leading to coma and respiratory depression. Hypotension is also documented.
Dose-Related Risk Factors The risk of severe outcomes, including fatalities, is significantly increased when Delto is used concurrently with other CNS depressants, notably opioids and alcohol.
Population-Specific Note Geriatric patients may be especially susceptible to profound CNS depressant effects.

Emergency Actions and Help-Seeking Requirements

If an overdose is suspected, official guidance explicitly mandates that you seek immediate medical attention by calling emergency services (e.g., 911) or a Poison Control Center immediately.

Immediate medical help is required if the person is unresponsive, has trouble breathing, or exhibits signs of coma. Treatment is described as symptomatic and supportive, focusing on maintaining the airway and monitoring cardiovascular and respiratory function. The specific benzodiazepine antagonist, Flumazenil, is available for use but carries a regulatory warning regarding the potential to precipitate seizures.

Therapeutic Uses of Delto

What Delto Treats: Main Uses and Benefits

The medication is applied in managing two main conditions: Generalized Anxiety Disorder (GAD) and Panic Disorder. It is used across domains where short-term symptomatic assistance is appropriate for intense, disruptive symptoms.

Delto is commonly used for conditions characterized by periods of heightened symptoms and episodic manifestations, including anxiety associated with depression, and panic disorder with agoraphobia. It is used for managing symptom clusters that may become intense or disruptive, such as overwhelming fear, the feeling of losing control, and symptoms related to heightened physiological activity.

“It is applied when chronic excessive worry, persistent apprehension, and associated muscle tension create noticeable functional strain.”

This therapeutic support contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability when symptoms are more noticeable. It is relevant when symptoms interfere with daily functioning.

Quick Fact: Relevant for Symptoms associated with Acute Anxiety and Panic Episodes

Acute Crisis Intervention and Panic Episodes

Delto is commonly used during episodes of sudden symptom escalation often associated with panic attacks. It is used for managing symptom clusters that may become intense or disruptive, such as overwhelming fear and symptoms related to heightened physiological activity, like palpitations and trembling. It provides support that helps ease the overall symptom burden, offering symptomatic relief that helps patients cope more steadily with difficult, recurrent episodes.

Managing Persistent Worry and Somatic Tension

The medication is relevant in conditions presenting with systemic or localized discomfort, such as the persistent psychological symptoms often associated with Generalized Anxiety Disorder. It is applied when chronic excessive worry and associated muscle tension create noticeable functional strain. Delto contributes to improving comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH DailyMed official prescribing information

Eligibility and Restrictions for Use

Eligibility Scope

The use of Delto (Alprazolam) is defined by official regulatory rules, establishing eligibility primarily for the adult population (18 years of age and older). Safety and effectiveness have not been established in pediatric patients under 18 years old.

Absolute Contraindications

Delto is contraindicated and must not be used by specific populations as stated in regulatory labeling. These absolute exclusions include:

  • Patients with a known hypersensitivity to Alprazolam or any other benzodiazepine.
  • Patients with acute narrow-angle glaucoma.
  • Patients concurrently taking strong CYP3A inhibitors, such as ketoconazole or itraconazole.

Conditional and Restricted Use

Certain populations are classified as requiring caution or have documented use limitations:

  • Pregnancy and Lactation: Use is generally not recommended during pregnancy or by breastfeeding women.
  • Organ Function and Comorbidity: Use is restricted in patients with severe hepatic impairment, severe respiratory insufficiency, and a history of drug or alcohol dependence.
  • Geriatric Patients: Older adults are a permitted population, but regulatory documents classify them as requiring special caution due to increased sensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Delto (alprazolam) is based on its metabolism via the Cytochrome P450 3A4 (CYP3A4) enzyme and its classification as a Central Nervous System (CNS) depressant.

Pharmacokinetic Interactions (Exposure Modification)

Co-administration with potent CYP3A4 inhibitors is officially contraindicated due to the significant risk of reduced clearance and increased Delto plasma concentration. Specifically, the strong antifungal medicines ketoconazole and itraconazole are prohibited for concomitant use. Other CYP3A4 inhibitors, such as nefazodone, fluvoxamine, and erythromycin, also result in elevated Delto exposure. Conversely, CYP3A4 inducers like carbamazepine increase Delto's clearance, which may reduce its concentration.

Pharmacodynamic Interactions and Substance Use

Interactions that cause additive CNS depression are clinically significant. Co-administration with opioid medicinal products may result in profound sedation and respiratory depression. The use of alcohol is noted to potentiate the sedative effects of Delto. Additionally, the regulatory information notes that cigarette smoking may reduce Delto concentrations by up to 50%, and for the extended-release formulation, a high-fat meal can increase the maximum plasma concentration.

Mechanism of Action

The mechanism of Delto (Alprazolam) fundamentally involves the GABA A receptor complex, the principal site for fast inhibitory signaling in the brain. The molecule functions as a positive allosteric modulator, binding to a specific site distinct from the GABA neurotransmitter binding site. This interaction causes a subtle change in the receptor's shape, which increases the receptor's response to GABA by increasing the frequency of its integral chloride ion ( Cl^-) channel opening.

The enhanced flow of chloride ions into the nerve cell causes the postsynaptic membrane to become hyperpolarized (more negatively charged). This makes the neuron profoundly less likely to fire an electrical signal, initiating a rapid mechanistic cascade that results in the systemic dampening of nerve signal transmission across critical regions of the central nervous system (CNS). This process produces the physiological consequences of central nervous system depression and centrally mediated reduction in muscle tone.

The continuous GABA-enhancing activity of the mechanism is physiologically constrained by a process known as neuroadaptation. Chronic modulation of the GABA A receptor complex can lead to functional changes, such as receptor downregulation or uncoupling, as part of a process to re-establish physiological equilibrium. This adaptation directly translates into functional tolerance, diminishing the magnitude of the initial GABA-enhancing effect and requiring the continuous presence of GABA.

Dosage and Administration Information

How to Use Delto (Alprazolam)

Delto is exclusively administered via the oral route, with usage patterns defined by the specific dosage form—immediate-release (IR), extended-release (ER), or orally disintegrating tablet (ODT)—and the condition being managed.


Official Dosing and Frequency

Usage Entity Usage Parameters
Route of Administration Oral route for all forms.
Frequency (IR/ODT) Typically administered three times daily (TID) in divided, equally-spaced doses.
Frequency (ER) Administered once daily, preferably in the morning.
Starting Doses (Standard Adult) For Anxiety, 0.25 mg to 0.5 mg; for Panic Disorder, 0.5 mg.
Maximum Daily Dose Up to 4 mg for Anxiety (IR/ODT) and up to 10 mg for Panic Disorder (IR, ODT, or ER).

Administration and Duration Protocol

Standard protocols involve precise administration steps. Delto tablets may be taken with or without food. However, Extended-Release tablets must be swallowed whole and must not be crushed, divided, or chewed, as this compromises the intended release profile. Orally Disintegrating Tablets (ODT) require specific handling, needing to be removed from the blister with dry hands and placed on the tongue for rapid dissolution.

The use of Delto is intended for the shortest possible time, often limited to a maximum duration of 8 to 12 weeks, including the necessary tapering period. To discontinue treatment, the dosage must be gradually reduced, with the daily dose decreased by no more than 0.5 mg every three days, a standard procedure to mitigate the risk of withdrawal.

Lower initial daily dosages, typically 0.25 mg or 0.5 mg, are required for vulnerable populations, including older adults, debilitated patients, and those with severe hepatic impairment, to ensure appropriate exposure.

Recent Clinical Evidence

Delto (delgocitinib cream 20 mg/g) is a topical pan-Janus kinase (JAK) inhibitor developed as a treatment for moderate to severe chronic hand eczema (CHE) in adults.

Key Phase 3 Trials (DELTA 1 & 2)

The efficacy and safety of Delto cream were primarily established in two Phase 3, randomized, double-blind, vehicle-controlled, multi-center trials: DELTA 1 and DELTA 2. These studies included adult participants with moderate to severe CHE who had an inadequate response to or for whom topical corticosteroids were medically inadvisable.

  • Efficacy vs. Vehicle: In both 16-week trials, a significantly greater proportion of patients treated with Delto cream achieved Investigator’s Global Assessment for Chronic Hand Eczema (IGA-CHE) treatment success (a score of 'clear' or 'almost clear') compared to those receiving the cream vehicle (placebo). Delto also demonstrated superior improvements in other key endpoints, including reduction in the Hand Eczema Severity Index (HECSI) score and improvements in patient-reported symptoms like itch and pain.

  • Safety Profile: Across both studies, Delto was generally well-tolerated over the 16-week period. The proportion of patients who reported adverse events was similar between the Delto group and the vehicle group. The most frequently reported adverse events in both treatment groups included nasopharyngitis and COVID-19, suggesting a favorable local safety profile compared to systemic risks often associated with oral treatments.

Active-Controlled Comparison (DELTA FORCE)

A separate 24-week, randomized, Phase 3 trial, DELTA FORCE, provided a head-to-head comparison of topical Delto cream against oral alitretinoin capsules (the only approved systemic drug for severe CHE). This trial demonstrated that Delto cream offered superior efficacy in reducing HECSI score from baseline to week 12, the primary endpoint, and at week 24. Furthermore, Delto was associated with a more favorable safety profile than oral alitretinoin, with fewer patients in the Delto group reporting adverse events overall.

Frequently Asked Questions (FAQ)

Common questions about Delto (FAQ)


Q: Is Delto the same as [Name of Competitor Drug/Chemical]?

Delto is the brand name for the active ingredient alprazolam. This substance is a prescription medication classified as a triazolobenzodiazepine, which belongs to a larger family of medicines known as central nervous system depressants. You can check the official product labels for any other medicine to see if it shares the same active component.


Q: Does Delto have to be taken forever?

Official guidance indicates that use is generally intended for the shortest possible time, with duration often limited to a period of up to 8 to 12 weeks, which includes the necessary tapering period. The medicine should only be used as long as directed by a healthcare professional.


Q: Can Delto stop working after a while?

Regulatory documents describe a phenomenon called functional tolerance or neuroadaptation. This process means that over time, the body may become accustomed to the drug, which could potentially diminish the magnitude of the clinical effect.


Q: Are the side effects of Delto temporary?

Official sources do not explicitly classify common side effects as temporary or permanent. However, effects like drowsiness and sedation are directly related to the presence of the drug in the body. If the medicine is discontinued gradually as directed by a healthcare professional, these effects are typically not long-lasting.


Q: Do people gain weight while taking Delto?

Clinical trials reported that changes in appetite or weight are possible adverse reactions. The official documents list both weight loss and weight gain as commonly reported effects during the period of use.


Q: Can Delto affect my mood?

Yes, official safety information lists several mood-related changes as reported adverse reactions. These include anxiety and depression as common effects, and rarely, more significant shifts like hypomania or mania have been documented in post-marketing surveillance.


Q: Can people with kidney issues use Delto?

The body primarily breaks down and eliminates alprazolam through hepatic metabolism (the liver), rather than relying heavily on the kidneys. Regulatory documents do not specify a dose adjustment based on renal (kidney) function, as the drug is primarily metabolized by the liver.


Q: Can I take Delto with over-the-counter pain relievers like ibuprofen?

Official regulatory documents do not list a specific interaction with common over-the-counter pain relievers like ibuprofen. However, Delto is a Central Nervous System (CNS) depressant. Using it alongside other CNS depressants could lead to additive effects, resulting in increased drowsiness or sedation.


Q: Does Delto interact with birth control pills?

Some official information suggests that oral contraceptives may affect how the body metabolizes (breaks down) certain benzodiazepines like alprazolam. This could potentially increase the concentration of Delto in the bloodstream, a factor noted in official information.


Q: What foods should be avoided when using Delto?

Regulatory documents specifically advise caution regarding grapefruit or grapefruit juice, as these may increase the drug's effects. Additionally, consuming a high-fat meal may increase the maximum concentration of the extended-release formulation of the medicine.


Q: Is there a generic version of Delto available?

Yes. The active ingredient in Delto, which is alprazolam, is available as a generic drug. The FDA has approved multiple generic versions of the medicine.


Q: Why does Delto need to be taken at a specific time of day?

The recommended dosing schedule is based on the formulation of the tablet. The immediate-release form is usually taken in divided, equally-spaced doses. The extended-release form is administered once daily, preferably in the morning, to provide a sustained level of the medicine throughout the day.


Q: Is it safe to drink coffee or caffeine while on Delto?

Regulatory documents do not list a direct drug-drug interaction with caffeine, but they note that Delto is a Central Nervous System (CNS) depressant while caffeine is a CNS stimulant.


Q: How is Delto different from other medicines for the same condition?

Delto is classified as a triazolobenzodiazepine, which is a specific type of Central Nervous System (CNS) depressant. It works by enhancing the function of the inhibitory neurotransmitter, GABA, leading to a general calming effect in the brain.


Q: Can Delto be split or crushed?

Official instructions state that Extended-Release tablets must be swallowed whole and must not be crushed, divided, or chewed, as this compromises the intended slow-release of the medication. Separate instructions apply to the immediate-release tablet forms.


Q: What happens if I accidentally take two doses of Delto?

Symptoms of overdose reported in regulatory documents may include drowsiness, confusion, impaired coordination, diminished reflexes, and potentially loss of consciousness.


Q: How quickly does Delto leave the system?

The elimination of the drug from the body is measured by its half-life. The mean plasma elimination half-life of alprazolam has been reported to be approximately 11.2 hours in healthy adults.


Q: Is Delto often prescribed with other medicines?

Official labeling provides extensive information about known interactions when Delto is used concomitantly (at the same time) with other medicines, including warnings about using it with opioids and contraindications with strong CYP3A4 inhibitors.


Q: Is the list of side effects in the official documents complete?

Official safety documents list adverse reactions based on their frequency in clinical trials, but they also include reactions reported later during post-marketing surveillance. These post-marketing reports include events where the exact incidence is sometimes not known.


Q: Are there different strengths of Delto?

Yes, the medication is available in several strengths across its different oral forms, as listed in the official documents. For example, the immediate-release tablets are available in strengths like 0.25 mg, 0.5 mg, 1 mg, and 2 mg.


Q: Does Delto make you feel sleepy or drowsy?

Yes. Drowsiness and sedation are listed among the most commonly reported adverse reactions in clinical trials. They are classified as very common effects, reported with an incidence of ge 10%.


Q: Can Delto cause stomach upset?

Nausea and constipation are listed among the common gastrointestinal adverse reactions reported in regulatory safety information. If you experience these effects, they should be reported to your healthcare provider.


Q: Is it normal to have vivid dreams when taking Delto?

Official safety information has reported dream abnormalities as an adverse event. This effect was reported in a small percentage (1.8%) of patients during clinical trials for panic disorder.


Q: Do older people react differently to Delto?

Yes, official documents note that older adults may exhibit increased sensitivity to the effects on the Central Nervous System (CNS). Pharmacokinetic studies also indicate that the mean elimination half-life is typically longer in the elderly compared to younger adults.


Q: What are the main research findings about Delto's effectiveness?

Clinical studies have typically been structured to demonstrate effectiveness for generalized anxiety disorders over a duration of up to four months, and for panic disorder, up to eight months.


Q: How does Delto affect blood pressure or heart rate?

Official safety information lists common effects like lightheadedness and dizziness. These symptoms may be associated with changes in blood pressure, a known effect of Central Nervous System depressants.


Q: Does Delto affect fertility?

Regulatory studies examining the drug's effect on fertility were conducted in animals (rats) and found no evidence of impairment at high doses.

How should Delto be stored and disposed of?

Storage

To maintain the quality and effectiveness of Delto, it must be stored according to specific guidelines. Always keep the medication in its original container and follow the temperature requirements stated on the packaging or patient information leaflet. Typically, medicines should be stored in a cool, dry place, protected from moisture and heat, unless refrigeration is specifically directed. Crucially, all medication must be kept out of the sight and reach of children and pets to prevent accidental ingestion or misuse.

Disposal

Proper disposal is essential to prevent harm to others and the environment. Do not flush Delto down the toilet or pour it down a drain unless the product information specifically instructs you to do so. The preferred method for discarding unused or expired Delto is through a formal drug take-back program, such as those provided by pharmacies or authorized law enforcement events. If a take-back program is unavailable, consult with a pharmacist or healthcare professional for the safest at-home disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Delto found in:

A-Z Index: